Genome-wide association studies have examined the common genetic variation in the population that is associated with breast cancer and have repeatedly identified fibroblast growth factor receptor 2 (FGFR2) as their ‘top hit’ (3–11), with the risk variants conferring increased risk for oestrogen receptor-positive (ER+) disease. This evidence concerns the gene FGFR2 and breast carcinoma.